Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
15. Februar 2023 07:00 ET
|
Passage Bio
– Updated interim data from first six patients in Phase 1/2 Imagine-1 study of PBGM01 for GM1 Gangliosidosis to be shared in oral platform and poster presentations PHILADELPHIA, Feb. 15, 2023 ...
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20. Januar 2023 16:01 ET
|
Passage Bio
PHILADELPHIA, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study
14. Dezember 2022 07:00 ET
|
Passage Bio
Interim safety data up to 20 months showed the low and high dose of PBGM01 were well tolerated and had a favorable safety profileIntra-cisterna magna administration of PBGM01 resulted in...
Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates
10. November 2022 07:00 ET
|
Passage Bio
Dosed first patient in final cohort, Cohort 4, in dose-ascending phase of Imagine-1 clinical trial for GM1 gangliosidosis; expect to dose the final patient in this phase of the trial by year-endPlan...
Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day
08. November 2022 07:00 ET
|
Passage Bio
PHILADELPHIA, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022
03. November 2022 07:30 ET
|
Passage Bio
PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14. Oktober 2022 16:01 ET
|
Passage Bio
PHILADELPHIA, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer
10. Oktober 2022 07:00 ET
|
Passage Bio
PHILADELPHIA, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio to Present at Chardan’s 6th Annual Genetic Medicines Conference
26. September 2022 07:00 ET
|
Passage Bio
PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
19. August 2022 16:01 ET
|
Passage Bio
PHILADELPHIA, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...